ASH 2017 | Treating lymphoma beyond progression
Treating cancer beyond progression is an important option to be considered in cases where the benefits outweigh the risks. Speaking from the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA, Graham Collins, MRCP, FRCPath, DPhil, of Oxford University Hospitals NHS Foundation Trust, Oxford, UK, discusses treating patients with lymphoma beyond progression. Dr Collins highlights data discussed from the Phase II CheckMate 205 study (NCT02181738), in which certain patients re-entered remission following PET-assessed progression following another course of treatment. He highlights how data such as this informs clinicians decisions on continuing treatment.
Get great new content delivered to your inboxSign up